RESUMO
BACKGROUND: In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration. This article describes a budget impact analysis of introducing infliximab SC to the Big-5 European (E5) market (Germany, France, Italy, Spain and UK) for 5 years, from the healthcare payer's perspective. METHODS: A prevalence-based budget impact model was developed to examine the financial impact of infliximab SC. "World with" versus "world without" infliximab SC scenarios were compared, including the potential administration costs of IV administration. RESULTS: Introducing infliximab SC in patients with Crohn's disease (CD) for 5 years resulted in cost savings of 42.0 million in the UK, 59.4 million in Germany, and 46.4 million in France and Italy, but increased budget expenditure in Spain by 3.8 million. For ulcerative colitis (UC), cost savings of 42.7 million in the UK, 44.9 million in Germany, 44.3 million in France, and 53.0 million in Italy occurred, but with no savings in Spain for 5 years. Cost-savings per patient was calculated by diving the net budget saving by number of treatment eligible patients. Maximum and minimum saving per patient per year ranged between 38.25 and 575.74 in CD, both from Germany, and 105.06 (France) and 647.25 (Germany) in UC. CONCLUSION: Healthcare payers in the UK, Germany, France, and Italy, but not in Spain, will make budget savings by using infliximab SC for the treatment of inflammatory bowel disease.
Assuntos
Anticorpos Monoclonais , Doenças Inflamatórias Intestinais , Humanos , Infliximab/uso terapêutico , Redução de Custos , Doenças Inflamatórias Intestinais/tratamento farmacológicoRESUMO
BACKGROUND: CT-P13 subcutaneous (SC)-the first and only SC version of infliximab-is approved by the European Medicines Agency for the treatment of rheumatoid arthritis (RA). This new mode of infliximab administration will allow patients to self-inject at home, significantly reducing the number of outpatient visits and costs of intravenous (IV) administration. This paper describes the economic impact of introducing CT-P13 SC to the market from the UK societal perspective. OBJECTIVE: The budget impact analysis was conducted to assess the financial impact of the adoption of CT-P13 SC over a 5-year period. METHODS: A prevalence-based budget impact model was developed incorporating epidemiological data, administration cost data, and market share data. The analysis compared a "world with" CT-P13 SC scenario to a "world without" CT-P13 SC. A sensitivity analysis included dose escalation up to 4.1 mg/kg to reflect the real-world care delivery setting. RESULTS: Compared to the "world without" scenario, the introduction of CT-P13 SC resulted in cost savings of £69.3 million in the UK over a 5-year period. In the scenario analysis, the saving increased to £173.5 million over 5 years. CONCLUSION: Use of CT-P13 SC may lead to substantial cost savings for the UK society.